Before you invest
Why wait for Phase II data to make key decisions?
Patient data and machine learning can raise confidence in a go/no-go decision long before a readout. These lessons show how we read the record of past programs.
Investment lessons series
Eleven lessons, one method
Each lesson takes a target class, follows its clinical programs, and names the pattern that separated the ones that worked.
Start with Rule of 5.
Investment lessons
Rule of 5
Five patterns behind oncology program outcomes
PDFOpen →
Investment lessons
KRAS
KRAS G12C inhibitors: KRAS is not a solo driver, so combinations will be tissue-specific.
Read online + PDFOpen →
Investment lessons
KRAS, part 2
Pancreatic cancer: SMAD4 loss opens combination options for KRAS inhibitors.
Read online + PDFOpen →
Investment lessons
FGFR2
A $1.9B+ gastric cancer program: FGFR2 overexpression did not make it a solo driver.
Read online + PDFOpen →
Investment lessons
MDM2
$1B+ invested: resistance via MDM4 and hotspot TP53 mutations exists before treatment begins.
Read online + PDFOpen →
Investment lessons
PD-L1 × VEGF
Coming late is expensive: VEGF synergy with PD-L1 was visible in patient data before Phase II.
Read online + PDFOpen →
Investment lessons
EGFR × TGFβ
Second-best tissue: EGFR × TGFβ vs EGFR × LGR5 in head and neck cancer.
Read online + PDFOpen →
Investment lessons
HER2
Why trastuzumab worked: HER2 is a solo driver in breast cancer, much less so in stomach cancer.
Read online + PDFOpen →
Investment lessons
PIK3CA
$2B+ for a PI3Kα inhibitor: PIK3CA is not a solo driver, and amplification may shape response.
Read online + PDFOpen →
Investment lessons
EGFR
Amplified EGFR is a team player: why mAbs underperformed and where bispecifics fit.
Read online + PDFOpen →
Investment lessons
WRN
The $400M algorithm mistake: a WRN mutation type missed by public algorithms.
Read online + PDFOpen →
More insights are added as programs read out. Ask for a due-diligence assessment of a specific asset through the contact form.